TRPV4 Mechanotransduction in Fibrosis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Fibrosis is an irreversible, debilitating condition marked by the excessive production of extracellular matrix and tissue scarring that eventually results in organ failure and disease. Differentiation of fibroblasts to hypersecretory myofibroblasts is the key event in fibrosis. Although both soluble and mechanical factors are implicated in fibroblast differentiation, much of the focus is on TGF-β signaling, but to date, there are no specific drugs available for the treatment of fibrosis. In this review, we describe the role for TRPV4 mechanotransduction in cardiac and lung fibrosis, and we propose TRPV4 as an alternative therapeutic target for fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TGF-β1 Signaling and Tissue Fibrosis
Kim, K. K., Sheppard, D., & Chapman, H. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022293 · Cited by 800 · cited 1×
“Most studies demonstrated that TGF-β and it’s signaling plays a central role in the initiation and progression of fibroblasts differentiation [28,29].”
BackgroundTRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice
Rahaman, S. O., Grove, L. M., Paruchuri, S., Southern, B. D., Abraham, S., Niese, K. A., Scheraga, R. G., Ghosh, S., Thodeti, C. K., Zhang, D. X., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75331 · Cited by 310
Self-citationWillette, R. N., Bao, W., Nerurkar, S., Yue, T.-L., Doe, C. P., Stankus, G., Turner, G. H., Ju, H., Thomas, H., Fishman, C. E., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.134551 · Cited by 300
Pakshir, P., Noskovicova, N., Lodyga, M., Son, D. O., Schuster, R., Goodwin, A., Karvonen, H., & Hinz, B. (2020) · Journal of Cell Science · doi:10.1242/jcs.227900 · Cited by 293
Adapala, R. K., Thoppil, R. J., Ghosh, K., Cappelli, H. C., Dudley, A. C., Paruchuri, S., Keshamouni, V, Klagsbrun, M., Meszaros, J. G., Chilian, W. M., et al. (2016) · Oncogene · doi:10.1038/onc.2015.83 · Cited by 153 · cited 4×
“TRPV4 normalized abnormal vasculature and improved cancer therapy [57].”
BackgroundInfluentialSelf-citationYAP1 Is a Driver of Myofibroblast Differentiation in Normal and Diseased Fibroblasts
Piersma, B., de Rond, S., Werker, P. M. N., Boo, S., Hinz, B., van Beuge, M. M., & Bank, R. A. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.08.011 · Cited by 135
TRPV4 channel activation selectively inhibits tumor endothelial cell proliferation
Thoppil, R. J., Adapala, R. K., Cappelli, H. C., Kondeti, V., Dudley, A. C., Gary Meszaros, J., Paruchuri, S., & Thodeti, C. K. (2015) · Scientific Reports · doi:10.1038/srep14257 · Cited by 63 · cited 1×
“Furthermore, we found that the absence of TRPV4 increases endothelial proliferation via upregulating cyclin-ERK-pathway [68].”
BackgroundSelf-citation
Cited by
Fibroblast and myofibroblast activation in normal tissue repair and fibrosis
Younesi, F. S., Miller, A. E., Barker, T. H., Rossi, F. M. V., & Hinz, B. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00716-0 · Cited by 681
The Role of Myofibroblasts in Physiological and Pathological Tissue Repair
Schuster, R., Younesi, F., Ezzo, M., & Hinz, B. (2023) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041231 · Cited by 232
(2025) · doi:10.3389/fimmu.2025.1670213 · Cited by 29
Targeting tumor extracellular matrix with nanoparticles to circumvent therapeutic resistance
Ding, X., Liang, Y., Zhou, S., Wu, Y., Sałata, P., Mikolajczk-Martinez, A., Khosrawipour, V., & Zhang, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113786 · Cited by 20
Metadata
- Authors
- Adapala, R. K., Katari, V., Teegala, L. R., Thodeti, S., Paruchuri, S., & Thodeti, C. K.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-11-06
- Volume
- 10
- Issue
- 11
- Pages
- 3053
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3212083965
- Cited by
- 55
- References
- 7
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.